Alert detail
FDA Approval: RHAPSIDO (REMIBRUTINIB) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA218436Specialty: HematologyAdded: 10/10/2026Effective: September 30, 2025federal register
What changed
Oral BTK inhibitor remibrutinib routes through Part D specialty pharmacy.
Who’s affected: Hematology billing teams · Effective: September 30, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.